EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Substrate specificity of human chymotrypsin-like protease (CTRL) characterized by phage display-selected small-protein inhibitors

Bálint Zoltán Németh, Zoltán Attila Nagy, Bence Kiss, Gabriella Gellén, Gitta Schlosser, Alexandra Demcsák, Andrea Geisz, Eszter Hegyi, Miklós Sahin-Tóth, Gábor Pál

Pancreatology · 2023

DOI: 10.1016/j.pan.2023.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2023. Verfasst von Bálint Zoltán Németh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/C, H-1117, Budapest, Hungary. Hauptthemen laut MEDLINE: Chymases, Chymotrypsin, Protease Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chymotrypsin-like protease (CTRL) is one of the four chymotrypsin isoforms expressed in the human exocrine pancreas. Human genetic and experimental evidence indicate that chymotrypsins B1, B2, and C (CTRB1, CTRB2 and CTRC) are important not only for protein digestion but also for protecting the pancreas against pancreatitis by degrading potentially harmful trypsinogen. CTRL has not been reported to play a similar role, possibly due to its low abundance and/or different substrate specificity. To address this problem, we investigated the specificity of the substrate-binding groove of CTRL by evolving the substrate-like canonical loop of the Schistocerca gregaria proteinase inhibitor 2 (SGPI-2), a small-protein reversible chymotrypsin inhibitor to bind CTRL. We found that phage-associated SGPI-2 variants with strong affinity to CTRL were similar to those evolved previously against CTRB1, CTRB2 or bovine chymotrypsin A (bCTRA), indicating comparable substrate specificity. When tested as recombinant proteins, SGPI-2 variants inhibited CTRL with similar or slightly weaker affinity than bCTRA, confirming that CTRL is a typical chymotrypsin. Interestingly, an SGPI-2 variant selected with a Thr29His mutation in its reactive loop was found to inhibit CTRL strongly, but it was digested rapidly by bCTRA. Finally, CTRL was shown to degrade human anionic trypsinogen, however, at a much slower rate than CTRB2, suggesting that CTRL may not have a significant role in the pancreatic defense mechanisms against inappropriate trypsinogen activation and pancreatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChymasesChymotrypsinProtease InhibitorsAnimalsCattleHumansPancreatitisSubstrate SpecificityTrypsinogenPeptide Library

Stichwörter der Autor:innen

Directed protein evolutionHuman chymotrypsin-like enzymePhage displaySerine proteinaseSerine proteinase inhibitor

Substanzen

ChymasesChymotrypsinProtease InhibitorsTrypsinogenPeptide Library

Autor:innen und Institutionen

  • Department of Biochemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/C, H-1117, Budapest, Hungary.
  • Department of Analytical Chemistry, MTA-ELTE Lendület Ion Mobility Mass Spectrometry Research Group, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/A, Budapest, H-1117, Budapest, Hungary.
  • Department of Surgery, University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Department of Surgery, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
  • Institute for Translational Medicine, University of Pécs, Medical School, H-7624, Pécs, Hungary.
  • Department of Biochemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/C, H-1117, Budapest, Hungary. Electronic address: gabor.pal@ttk.elte.hu.

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • European Union
  • Hungarian Scientific Research Fund
  • Hungarian Academy of Sciences
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • European Regional Development Fund
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Németh, B. Z., Nagy, Z. A., Kiss, B., Gellén, G., Schlosser, G., Demcsák, A., Geisz, A., Hegyi, E., Sahin-Tóth, M., & Pál, G. (2023). Substrate specificity of human chymotrypsin-like protease (CTRL) characterized by phage display-selected small-protein inhibitors. Pancreatology. https://doi.org/10.1016/j.pan.2023.08.004

Vancouver

Németh BZ, Nagy ZA, Kiss B, Gellén G, Schlosser G, Demcsák A, et al. Substrate specificity of human chymotrypsin-like protease (CTRL) characterized by phage display-selected small-protein inhibitors. Pancreatology. 2023. doi:10.1016/j.pan.2023.08.004

BibTeX
@article{Nmeth2023,
  author = {Németh, Bálint Zoltán and Nagy, Zoltán Attila and Kiss, Bence and Gellén, Gabriella and Schlosser, Gitta and Demcsák, Alexandra and Geisz, Andrea and Hegyi, Eszter and Sahin-Tóth, Miklós and Pál, Gábor},
  title = {Substrate specificity of human chymotrypsin-like protease (CTRL) characterized by phage display-selected small-protein inhibitors},
  journal = {Pancreatology},
  year = {2023},
  doi = {10.1016/j.pan.2023.08.004}
}
Kostenlos starten →